Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.69 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | ABL1 | P00519 | 3/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.47 |
| ▸ | BCR | P11274 | 3/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21903457 | 0.91 | APP (0.75) | APPKCNH2CA12CA1CA2 | |
| SCHEMBL674764 | 0.88 | APP (0.77) | APPKCNH2CA12CA1CA2 | |
| SCHEMBL10300057 | 0.88 | APP (0.77) | APPKCNH2CA12CA1CA2 | |
| SCHEMBL674040 | 0.88 | ALDH1A1 (0.65) | APPCA12CA1CA2CA9 | |
| SCHEMBL1005880 | 0.87 | APP (0.77) | APPALDH1A1ABL1ABCB1BCR | |
| SCHEMBL9715639 | 0.85 | APP (0.74) | APPKCNH2CA12CA1CA2 | |
| SCHEMBL712263 | 0.85 | APP (0.52) | APPKCNH2CA12CA1CA2 | |
| SCHEMBL711936 | 0.82 | APP (0.48) | APPKCNH2CA12CA1CA2 | |
| SCHEMBL15014186 | 0.82 | APP (1.00) | APPKCNH2CA12CA1CA2 | |
| SCHEMBL15014229 | 0.82 | APP (1.00) | APPKCNH2CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280402-B1 | TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING | BIOMENDICS LLC (US) | 2024-06-05 | — | — | EP | disclosed |
| US-11786481-B2 | Formulation and process for modulating wound healing | BioMendics, LLC (US) | 2023-10-17 | — | — | US | disclosed |
| CN-116425607-A | Method for preparing cis-form or trans-form alkene by chromium-catalyzed intermediate alkyne selective hydrogenation | 四川大学 | 2023-07-14 | — | — | CN | disclosed |
| CN-113754619-B | Method for preparing polysubstituted benzofuran-4-formic acid compound under catalysis of ruthenium | 广州大学 | 2022-12-20 | — | — | CN | disclosed |
| US-20220296538-A1 | Substituted Tolans for the Modulation of Microbial Colonization | BioMendics, LLC (US) | 2022-09-22 | — | — | US | disclosed |
| US-11351126-B2 | Substituted tolans for the modulation of microbial colonization | BioMendics, LLC (US) | 2022-06-07 | — | — | US | disclosed |
| CN-113754619-A | Method for preparing polysubstituted benzofuran-4-formic acid compound under catalysis of ruthenium | 广州大学 | 2021-12-07 | — | — | CN | disclosed |
| US-20210228501-A1 | Formulation and Process for Modulating Wound Healing | BioMendics, LLC (US) | 2021-07-29 | — | — | US | disclosed |
| US-20200206154-A1 | Substituted Tolans for the Modulation of Microbial Colonization | BioMendics, LLC (US) | 2020-07-02 | — | — | US | disclosed |
| US-10426742-B2 | Formulation and process for modulating wound healing | BioMendics, LLC (US) | 2019-10-01 | — | — | US | disclosed |
| WO-2011009888-A2 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED ELECTRON RICH DIPHENYLACETYLENES | DSM IP ASSETS B.V. (NL) | 2011-01-27 | — | — | WO | disclosed |
| WO-2009126700-A1 | HYDROXYLATED TOLANS AND RELATED COMPOUNDS AS COSMETICS OR THERAPEUTICS FOR SKIN CONDITIONS | KENT STATE UNIVERSITY (US) | 2009-10-15 | — | — | WO | disclosed |
| WO-2008157745-A1 | ASCORBATE, VITAMIN K3 AND HYDROXYTOLANS IN THE TREATMENT OF CANCER | KENT STATE UNIVERSITY (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157787-A2 | HYDROXYLATED TOLANS AND RELATED COMPOUNDS IN THE TREATMENT OF CANCER | KENT STATE UNIVERSITY (US) | 2008-12-24 | — | — | WO | disclosed |
| US-7094809-B2 | Topical administration of dihydroxytoluene to block viral replication | NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE (US) | 2006-08-22 | — | — | US | disclosed |
| US-20030203974-A1 | Methods for treating subjects infected with herpes virus or Neisseria gonorrheae | DOCHERTY JOHN (US) | 2003-10-30 | — | — | US | disclosed |
| US-6599945-B2 | Administering a hydroxylated tolan to the host cell of a patient having or suspected having an infection induced by herpes virus | NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE | 2003-07-29 | — | — | US | disclosed |
| EP-1311254-A2 | METHODS FOR TREATING SUBJECTS INFECTED WITH A HERPES VIRUS OR i NEISSERIA GONORRHEAE /i | Northeastern Ohio Universities (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20020103262-A1 | Methods for treating subjects infected with a herpes virus or neisseria gonorrheae | KENT STATE UNIVERSITY | 2002-08-01 | — | — | US | disclosed |
| WO-2002013764-A2 | METHODS FOR TREATING SUBJECTS INFECTED WITH A HERPES VIRUS OR NEISSERIA GONORRHEAE | NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11786481-B2 | Formulation and process for modulating wound healing | SQSTM1, ATG7, TFEB | APP 4010/4885KCNH2 4241/4885CA12 4596/4885 |
| US-20200206154-A1 | Substituted Tolans for the Modulation of Microbial Colonization | LMAN1, DPM1, DSTN | APP 3466/4885KCNH2 3056/4885CA12 4823/4885 |
| US-20210228501-A1 | Formulation and Process for Modulating Wound Healing | ATG7, SQSTM1, ATF4 | APP 3850/4885KCNH2 4151/4885CA12 4648/4885 |
| US-10426742-B2 | Formulation and process for modulating wound healing | SQSTM1, ATG7, TFEB | APP 4010/4885KCNH2 4241/4885CA12 4596/4885 |
| US-11351126-B2 | Substituted tolans for the modulation of microbial colonization | LMAN1, DPM1, DSTN | APP 3466/4885KCNH2 3056/4885CA12 4823/4885 |
| US-20220296538-A1 | Substituted Tolans for the Modulation of Microbial Colonization | LMAN1, DPM1, DSTN | APP 3466/4885KCNH2 3056/4885CA12 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.